1-(4-nitrobenzyl)uracil | 7263-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-nitrobenzyl)uracil
• 英文别名: 1-(4-Nitrobenzyl)pyrimidine-2,4(1h,3h)-dione；1-[(4-nitrophenyl)methyl]pyrimidine-2,4-dione
• CAS: 7263-86-7
• 化学式: C₁₁H₉N₃O₄
• 分子量: 247.21
• InChiKey: BMTCZXDZXFKKMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  95.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-nitrobenzyl)uracil 在 三乙胺 、 tin(ll) chloride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 7.0h， 生成 1-(4-(cholesterylcarbonylamino)benzyl)uracil
  参考文献：
  名称：

  Gel formation properties of a uracil-appended cholesterol gelator and cooperative effects of the complementary nucleobases

  摘要：

  We designed and synthesized a uracil-appended cholesterol gelator (1) in order to control the gel stability and the gel morphology by addition of the complementary and non-complementary nucleobase derivatives. Compound 1 forms columnar stacks in cyclohexane due to the van der Waals interaction (cholesterol-cholesterol interaction) and the intergelator hydrogen bonding between uracil moieties. Addition of a 'monomeric' adenosine (3) into the gel only decreases the stability with increasing the concentration. The destabilization is ascribed to a lack of intergelator hydrogen bonding accompanied with forming the complementary base pairs between 1 and 3. In contrast, addition of adenine-appended cholesterol (7) induces a different behavior; with increasing 7 concentration the mixed gel is initially stabilized and then destabilized, giving rise to a maximum at the ratio of 1/7= 1:1 for the T-gel plot. One may consider, therefore, that when the additive has a common, column-forming cholesterol moiety, the cholesterol-cholesterol interaction can operate cooperatively with the complementary base pairing. In addition, the gel fiber structure is clearly changed by the addition of 7. Taking the fact that there is no report for such an additive effect inducing a structural change with maintaining the gel stability into consideration, our attempt combining cholesterol columnar stacks with the nucleobase additives provides a new methodology to control the stability and the morphology of organogels. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)01059-1
• 作为产物：
  描述：

  尿嘧啶 、 对硝基溴化苄 在 硫酸氢铵 、 六甲基二硅氮烷 作用下， 以 乙腈 为溶剂， 反应 40.0h， 以48%的产率得到1-(4-nitrobenzyl)uracil
  参考文献：
  名称：

  Gel formation properties of a uracil-appended cholesterol gelator and cooperative effects of the complementary nucleobases

  摘要：

  We designed and synthesized a uracil-appended cholesterol gelator (1) in order to control the gel stability and the gel morphology by addition of the complementary and non-complementary nucleobase derivatives. Compound 1 forms columnar stacks in cyclohexane due to the van der Waals interaction (cholesterol-cholesterol interaction) and the intergelator hydrogen bonding between uracil moieties. Addition of a 'monomeric' adenosine (3) into the gel only decreases the stability with increasing the concentration. The destabilization is ascribed to a lack of intergelator hydrogen bonding accompanied with forming the complementary base pairs between 1 and 3. In contrast, addition of adenine-appended cholesterol (7) induces a different behavior; with increasing 7 concentration the mixed gel is initially stabilized and then destabilized, giving rise to a maximum at the ratio of 1/7= 1:1 for the T-gel plot. One may consider, therefore, that when the additive has a common, column-forming cholesterol moiety, the cholesterol-cholesterol interaction can operate cooperatively with the complementary base pairing. In addition, the gel fiber structure is clearly changed by the addition of 7. Taking the fact that there is no report for such an additive effect inducing a structural change with maintaining the gel stability into consideration, our attempt combining cholesterol columnar stacks with the nucleobase additives provides a new methodology to control the stability and the morphology of organogels. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)01059-1

文献信息

• NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US20210130328A1

  公开（公告）日：2021-05-06

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及一种新型具有胸腺嘧啶骨架的化合物，这些化合物用于医药领域，特别是用于治疗癌症、HSP27相关疾病和囊性纤维化；以及含有至少一种这些化合物的药物产品。最后，提供了一种生产这些新型化合物的方法。这些化合物的一般化学式为式(I)，如权利要求书中进一步定义。
• COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：Technische Universität Dresden

  公开号：EP3819006A1

  公开（公告）日：2021-05-12

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。
• Compounds with thymine skeleton for use in medicine
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US11214564B2

  公开（公告）日：2022-01-04

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。
• Gel formation properties of a uracil-appended cholesterol gelator and cooperative effects of the complementary nucleobases
  作者：Erwin Snip、Kazuya Koumoto、Seiji Shinkai

  DOI：10.1016/s0040-4020(02)01059-1

  日期：2002.10

  We designed and synthesized a uracil-appended cholesterol gelator (1) in order to control the gel stability and the gel morphology by addition of the complementary and non-complementary nucleobase derivatives. Compound 1 forms columnar stacks in cyclohexane due to the van der Waals interaction (cholesterol-cholesterol interaction) and the intergelator hydrogen bonding between uracil moieties. Addition of a 'monomeric' adenosine (3) into the gel only decreases the stability with increasing the concentration. The destabilization is ascribed to a lack of intergelator hydrogen bonding accompanied with forming the complementary base pairs between 1 and 3. In contrast, addition of adenine-appended cholesterol (7) induces a different behavior; with increasing 7 concentration the mixed gel is initially stabilized and then destabilized, giving rise to a maximum at the ratio of 1/7= 1:1 for the T-gel plot. One may consider, therefore, that when the additive has a common, column-forming cholesterol moiety, the cholesterol-cholesterol interaction can operate cooperatively with the complementary base pairing. In addition, the gel fiber structure is clearly changed by the addition of 7. Taking the fact that there is no report for such an additive effect inducing a structural change with maintaining the gel stability into consideration, our attempt combining cholesterol columnar stacks with the nucleobase additives provides a new methodology to control the stability and the morphology of organogels. (C) 2002 Elsevier Science Ltd. All rights reserved.